Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d'arythmies ventriculaires et de mort subite

Scheen, André

doi:10.1016/j.mmm.2022.11.001

Request a copy

Article (Scientific journals)

Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d'arythmies ventriculaires et de mort subite

Scheen, André

2023 • In Médecine des Maladies Métaboliques, 17 (2), p. 157 - 168

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/305179

DOI
10.1016/j.mmm.2022.11.001

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2023 MMM SGLt2i reduisent FA et mort subite.pdf

Author postprint (1.2 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiac arrhythmias; Gliflozin; Heart failure; SGLT2 inhibitor; Stroke; Type 2 diabetes

Abstract :

[en] Patients with type 2 diabetes are exposed to a higher risk of cardiac arrhythmias, both supraventricular (atrial fibrillation or flutter) and ventricular (tachycardia, fibrillation, potentially leading to cardiac arrest and sudden cardiac death). The risk is even higher in the presence of heart failure. In the last few years, the interest for cardiac arrhythmias has been supplanted by the focus on “MACE 3-points” (cardiovascular mortality, nonfatal myocardial infarction and nonfatal stroke) and hospitalisations for heart failure. Sodium-glucose co-transporter type 2 inhibitors (SGLT2i) improve the cardiovascular prognosis and the outcome of heart failure. Findings derived from controlled clinical trials and large prospective cardiovascular outcome trials as well as observational retrospective cohort studies showed that SGLT2i may reduce the risk of atrial fibrillation/flutter, severe ventricular arrhythmias and cardiac arrest/sudden cardiac death, even if some data are not well supported and sometimes discordant. The relationships between these antiarrhythmic effects of SGLT2i and the occurrence of ischemic stroke, heart failure-related complications and overall cardiovascular mortality deserve special attention and are discussed in the present article. © 2022 Elsevier Masson SAS

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d'arythmies ventriculaires et de mort subite

Alternative titles :

[en] SGLT2 inhibitors reduce the risk of atrial fibrillation, ventricular arrhythmias and sudden cardiac death;

Publication date :

2023

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Volume :

Issue :

Pages :

157 - 168

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 13 July 2023

Statistics

Number of views

18 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Bell, D.S., Goncalves, E., Atrial fibrillation and type 2 diabetes : prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab 21 (2019), 210–217.
Wang, A., Green, J.B., Halperin, J.L., Piccini, J.P. Sr., Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 74 (2019), 1107–1115.
Scheen, A.J., Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on the differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Metab, 48:, 2022, 101390.
Bano, A., Rodondi, N., Beer, J.H., et al. Swiss-Investigators. Association of diabetes with atrial fibrillation phenotype and cardiac and neurological comorbidities: insights from the Swiss-AF study. J Am Heart Assoc, 10, 2021, e021800.
Gallego, M., Zayas-Arrabal, J., Alquiza, A., et al. Electrical features of the diabetic myocardium. Arrhythmic and cardiovascular safety considerations in diabetes. Front Pharmacol, 12, 2021, 687256 [eCollection 2021].
Aune, D., Schlesinger, S., Norat, T., Riboli, E., Diabetes mellitus and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 28 (2018), 543–556.
Singh, K.B., Nnadozie, M.C., Abdal, M., et al. Type 2 diabetes and causes of sudden cardiac death: a systematic review. Cureus, 13, 2021, e18145 [eCollection].
Vasiliadis, I., Kolovou, G., Mavrogeni, S., et al. Sudden cardiac death and diabetes mellitus. J Diabetes Complications 28 (2014), 573–579.
Walker, A.M., Cubbon, R.M., Sudden cardiac death in patients with diabetes mellitus and chronic heart failure. Diab Vasc Dis Res 12 (2015), 228–233.
Saltzman, H.E., Arrhythmias and heart failure. Cardiol Clin 32 (2014), 125–133 [ix].
Lip, G.Y., Heinzel, F.R., Gaita, F., et al. European heart rhythm association/heart failure association joint consensus document on arrhythmias in heart failure, endorsed by the heart rhythm society and the asia pacific heart rhythm society. Europace 18 (2016), 12–36.
Scheen, A.J., Études cardiovasculaires chez le patient diabétique de type 2 à risque: conclusions et impact des essais publiés en 2017-2018. Med Mal Metab 13 (2019), S10–S24.
Scheen, A.J., Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opin Drug Metab Toxicol 18 (2022), 381–393.
Scheen, A.J., Lancellotti, P., Inhibiteurs des SGLT2: nouvelle option pour prévenir ou traiter l'insuffisance cardiaque. Rev Med Liege 76 (2021), 248–255.
Scheen, A.J., Glucose-lowering agents and risk of cardiac arrhythmias. Acta Cardiol 25 (2022), 1–2, 10.1080/00015385.2022.2101875 [Online ahead of print].
Savarese, G., Butler, J., Lund, L.H., et al. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res 118 (2022), 2231–2252.
Sapp, J.L., Krahn, A., Stevenson, W.G., et al. Understanding, predicting, preventing, and treating ventricular arrhythmias: pushing sudden death into overtime. Can J Cardiol 38 (2022), 414–417.
Scheen, A.J., Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes Metab, 48, 2022, 101405.
Vrachatis, D.A., Papathanasiou, K.A., Iliodromitis, K.E., et al. Could sodium/glucose co-transporter-2 inhibitors have antiarrhythmic potential in atrial fibrillation? Literature review and future considerations. Drugs 83 (2021), 1381–1395.
Attachaipanich, T., Chattipakorn, S.C., Chattipakorn, N., Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure. J Cell Physiol 237 (2022), 2404–2419.
Granger, C.B., Mahaffey, K.W., Preventing atrial fibrillation with treatments for diabetes mellitus. Circulation 141 (2020), 1235–1237.
Zelniker, T.A., Bonaca, M.P., Furtado, R.H., et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 141 (2020), 1227–1234.
Butt, J.H., Docherty, K.F., Jhund, P.S., et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail 24 (2022), 513–525.
Artola Arita, V., Van Veldhuisen, D.J., Rienstra, M., Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation. Eur J Heart Fail 24 (2022), 526–528.
Zhou, Z., Jardine, M.J., Li, Q., CREDENCE Trial Investigators., et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke 52 (2021), 1545–1556.
Li, C., Yu, J., Hockham, C., et al. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: a secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes Obes Metab 24 (2022), 1927–1938.
Böhm, M., Slawik, J., Brueckmann, M., et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail 22 (2020), 126–135.
Patoulias, D., Papadopoulos, C., Doumas, M., Sodium-glucose co-transporter-2 inhibitors decrease the odds for atrial fibrillation in subjects with heart failure. J Stroke Cerebrovasc Dis, 31, 2022, 106257.
Ong, H.T., Teo, Y.H., Teo, Y.N., et al. Effects of sodium/glucose cotransporter inhibitors on atrial fibrillation and stroke: a meta-analysis. J Stroke Cerebrovasc Dis, 31, 2022, 106159.
Patoulias, D., Toumpourleka, M., Papadopoulos, C., Doumas, M., Meta-analysis evaluating the risk of atrial fibrillation with newer antidiabetics across the cardiovascular and renal outcome trials. Am J Cardiol 139 (2021), 139–141.
Zheng, R.J., Wang, Y., Tang, J.N., et al. Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 79 (2022), e145–e152.
Yin, Z., Zheng, H., Guo, Z., Effect of sodium-glucose co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized controlled trials. Front Cardiovasc Med, 9, 2022, 902923 [eCollection].
Pandey, A.K., Okaj, I., Kaur, H., et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Association, 10:, 2021 e022222.
Li, W.J., Chen, X.Q., Xu, L.L., et al. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol, 19, 2020, 130.
Li, D., Liu, Y., Hidru, T.H., et al. Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Endocrinol (Lausanne), 12, 2021, 619586 [eCollection].
Okunrintemi, V., Mishriky, B.M., Powell, J.R., Cummings, D.M., Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab 23 (2021), 276–280.
Fernandes, G.C., Fernandes, A., Cardoso, R., et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm 18 (2021), 1098–1105.
Li, H.L., Lip, G.Y., Feng, Q., et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol, 20, 2021, 100 [Erratum in: Cardiovasc Diabetol 2021; 20:177].
Wang, M., Zhang, Y., Wang, Z., et al. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis. J Thorac Dis 14 (2022), 1620–1637.
Birkeland, K.I., Jørgensen, M.E., Carstensen, B., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
Jhuo, S.J., Lin, T.H., Lin, Y.H., et al. Clinical observation of SGLT2 inhibitor therapy for cardiac arrhythmia and related cardiovascular disease in diabetic patients with controlled hypertension. J Pers Med, 12, 2022, 271.
Zhou, L., Yang, Y., Han, W., Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure. Ann Palliat Med 10 (2021), 10887–10895.
Chen, H.Y., Huang, J.Y., Siao, W.Z., Jong, G.P., The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol, 19, 2020, 73.
Ling, A.W., Chan, C.C., Chen, S.W., et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol, 19, 2020, 188.
Chan, Y.H., Chao, T.F., Chen, S.W., et al. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol, 21, 2022, 118.
Lee, S., Zhou, J., Leung, K.S., et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther, 2022, 10.1007/s10557-022-07319-x [Online ahead of print].
Hsiao, F.C., Yen, K.C., Chao, T.F., et al. New-onset atrial fibrillation in patients with type 2 diabetes treated with novel glucose lowering therapies. J Clin Endocrinol Metab 107 (2022), 2493–2499.
Li, C.X., Liang, S., Gao, L., Liu, H., Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS One, 16, 2021, e0244689 [eCollection].
Bonora, B.M., Raschi, E., Avogaro, A., Fadini, G.P., SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol, 20, 2021, 39.
Shi, W., Zhang, W., Zhang, D., et al. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: a network meta-analysis. Heart Rhythm 18 (2021), 1090–1096.
Li, W., Chen, X., Xie, X., et al. Comparison of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 79 (2022), 281–288.
Scheen, A.J., Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Kolesnik, E., Scherr, D., Rohrer, U., et al. SGLT2 inhibitors and their antiarrhythmic properties. Int J Mol Sci, 23, 2022, 1678.
Spallone, V., Valensi, P., SGLT2 inhibitors and the autonomic nervous system in diabetes: a promising challenge to better understand multiple target improvement. Diabetes Metab, 47, 2021, 101224.
Lim, V.G., He, H., Lachlan, T., et al. Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die. Europace 24 (2022), 1052–1057.
Sfairopoulos, D., Zhang, N., Wang, Y., et al. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace 24 (2022), 20–30.
Terpening, C.M., A call for more complete reporting of cardiovascular death. Circulation 140 (2019), 887–888.
Zinman, B., Wanner, C., Lachin, J.M., EMPA-REG OUTCOME Investigators., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
Fitchett, D., Inzucchi, S.E., Lachin, J.M., EMPA-REG OUTCOME Investigators., et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol 71 (2018), 364–367.
Curtain, J.P., Docherty, K.F., Jhund, P.S., et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42 (2021), 3727–3738.
Heerspink, H.J., Sjöström, C.D., Jongs, N., DAPA-CKD Trial Committees and Investigators., et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J 42 (2021), 1216–1227.
Ilyas, F., Jones, L., Tee, S.L., et al. Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. ESC Heart Fail 8 (2021), 4346–4352.
Packer, M., Anker, S.D., Butler, J., EMPEROR-Reduced Trial Investigators., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 (2020), 1413–1424.
Anker, S.D., Butler, J., Filippatos, G., EMPEROR-Preserved Trial Investigators., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 (2021), 1451–1461.
Fawzy, A.M., Rivera-Caravaca, J.M., Underhill, P., et al. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium glucose co-transporter 2 (SGLT2) inhibitor use in diabetic patients: insights from a global federated electronic medical record database. Diabetes Obes Metab, 2022, 10.1111/dom.14854 [Online ahead of print].
Hindricks, G., Potpara, T., Dagres, N., ESC Scientific Document Group., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42 (2021), 373–498 [Erratum in: Eur Heart J 2021; 42:507].
Bonnet, F., Scheen, A.J., Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. Diabetes Metab 43 (2017), 299–313.
Kwon, C.H., Kim, Y.J., Kim, M.J., et al. Effect of sodium-glucose cotransporter inhibitors on major adverse cardiovascular events and hospitalization for heart failure in patients with type 2 diabetes mellitus and atrial fibrillation. Am J Cardiol 178 (2022), 35–42.
Lăcătuşu, C.M., Grigorescu, E.D., Stătescu, C., et al. Association of antihyperglycemic therapy with risk of atrial fibrillation and stroke in diabetic patients. Medicina (Kaunas), 55, 2019, 592.
Rosano, G., Savarese, G., Inter-twinned relationship between heart failure and atrial fibrillation. Heart 106 (2020), 1125–1126.
Packer, M., Lam, C.S., Lund, L.H., Redfield, M.M., Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation 141 (2020), 4–6.
American Diabetes Association Professional Practice Committee, Draznin, B., Aroda, V.R., Bakris, G., et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 45 (2022), S125–S143.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Dyck, J.R., Sossalla, S., Hamdani, N., et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. J Mol Cell Cardiol 167 (2022), 17–31.
Light, P.E., Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. Eur Heart J 42 (2021), 3739–3740.
Lopaschuk, G.D., Verma, S., Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5 (2020), 632–644.
Shetty, S.S., Krumerman, A., Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. Cardiovasc Diabetol, 21, 2022, 119.
Lee, T.W., Lee, T.I., Lin, Y.K., et al. Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. Cell Mol Life Sci 78 (2021), 923–934.
Scheen, A.J., Dissecting the reduction in cardiovascular death with SGLT2 inhibitors: potential contribution of effects on ventricular arrhythmias and sudden cardiac death?. Diabet Epidemiol Manag, 8, 2022, 100107.
Jing, Y., Yang, R., Chen, W., Ye, Q., Anti-arrhythmic effects of sodium-glucose co-transporter 2 inhibitors. Front Pharmacol, 13, 2022, 898718 [eCollection].
Peng, X., Li, L., Zhang, M., et al. Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction. Front Physiol, 11, 2020, 912 [eCollection].
Scheen, A.J., Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep, 21, 2019, 70.
Bonnet, F., Scheen, A.J., Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 44 (2018), 457–464.
Andelova, K., Bacova, B.S., Sykora, M., et al. Mechanisms underlying antiarrhythmic properties of cardioprotective agents impacting inflammation and oxidative stress. Int J Mol Sci, 23, 2022, 1416.